Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which surgery saves sight better after eye injection infection?

NCT ID NCT07717944

Disease control Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study compares two surgical approaches for treating a serious eye infection (endophthalmitis) that can occur after an injection into the eye. One group receives a combined surgery that removes the eye's natural lens along with infected vitreous gel (phacovitrectomy), while the other has only the vitreous gel removed (vitrectomy alone). The main goal is to see which method leads to better vision three months after surgery, and to track complications and the need for additional procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a surgical procedure: phacovitrectomy (combined cataract removal and vitrectomy) or pars plana vitrectomy alone
What this could lead to
If one surgery proves better, it could guide surgeons on the best approach to save vision in patients with severe eye infections after injections.
What could go wrong
This is a small, retrospective study with only 40 patients, so results may not apply to everyone. Both surgeries carry risks like infection, bleeding, or vision loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jan 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Clinical diagnosis of acute post-intravitreal injection infectious endophthalmitis. * History of intravitreal injection before the onset of endophthalmitis. * Phakic eye at the time of presentation. * Eyes with persistent or worsening clinical signs despite initial intravitreal antibiotic therapy (vancomycin and ceftazidime), requiring surgical intervention. * Underwent either combined phacovitrectomy or pars plana vitrectomy alone as the primary surgical treatment. * Ability to complete at least 3 months of postoperative follow-up. Exclusion Criteria: * Endophthalmitis secondary to causes other than intravitreal injection (e.g., post-cataract surgery, glaucoma surgery, penetrating ocular trauma, or endogenous endophthalmitis). * Previous vitrectomy in the study eye. * Pre-existing ocular conditions likely to significantly affect visual outcomes, including retinal detachment, advanced optic neuropathy, advanced glaucoma, or dense corneal opacity. * Eyes with no visual potential before the onset of endophthalmitis. * Inability to complete the scheduled follow-up visits or missing primary outcome data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endophthalmitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endophthalmitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endophthalmitis Endophthalmitis postoperative Intravitreal injection patients

Contacts and locations

Locations

  • Benha University

    Banhā, Benha, 13111, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.